PGT152 light chain
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric(2) Consistent with protein copy count | Chain A; UniProt 132–239 | Mutation:N107K | PGT152 heavy chain × 1 (Q6N089) | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION;pH 4.2;293.15 K;40% PEG 600, 0.1M phosphate-citrate, pH 4.2, VAPOR DIFFUSION, temperature 293.15K | Resolution 1.83 Å R-free 0.210 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 4NUJ | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1HZH CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 ISOLATES: A TEMPLATE FOR HIV VACCINE DESIGN Deposited 2001-01-24 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain L
132–239(108 aa)
Chain M
132–239(108 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;295.5 K;NH4SO4, cacodylate, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 295.5K
|
Resolution 2.70 Å R-free 0.273 |
| 1N0X Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope Deposited 2002-10-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 6 PDB declaration: hexameric |
Chain L
132–239(108 aa)
Fragment:UNP residues 132-239
Chain M
132–239(108 aa)
Fragment:UNP residues 132-239
|
Not recorded | GOL GLYCEROL × 8 SO4 SULFATE ION × 4 CXS 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID × 1 K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 10.5;295.5 K;ammonium sulfate, lithium sulfate, CAPS buffer, pH 10.5, VAPOR DIFFUSION, SITTING DROP, temperature 295.5K
|
Resolution 1.80 Å R-free 0.252 |
| 3CFJ Crystal structure of catalytic elimination antibody 34E4, orthorhombic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
131–239(109 aa)
|
Not recorded | GOL GLYCEROL × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% MPEG 2000, 0.2M (NH4)2SO4, 0.1M ACETATE, PH 4.6, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 4.60
|
Resolution 2.60 Å R-free 0.253 |
| 3CFJ Crystal structure of catalytic elimination antibody 34E4, orthorhombic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
131–239(109 aa)
|
Not recorded | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% MPEG 2000, 0.2M (NH4)2SO4, 0.1M ACETATE, PH 4.6, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 4.60
|
Resolution 2.60 Å R-free 0.253 |
| 3CFJ Crystal structure of catalytic elimination antibody 34E4, orthorhombic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
131–239(109 aa)
|
Not recorded | GOL GLYCEROL × 1 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% MPEG 2000, 0.2M (NH4)2SO4, 0.1M ACETATE, PH 4.6, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 4.60
|
Resolution 2.60 Å R-free 0.253 |
| 3CFJ Crystal structure of catalytic elimination antibody 34E4, orthorhombic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain E
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;30% MPEG 2000, 0.2M (NH4)2SO4, 0.1M ACETATE, PH 4.6, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 4.60
|
Resolution 2.60 Å R-free 0.253 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 3 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain E
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain G
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain J
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 7 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain M
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 1 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3CFK Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form Deposited 2008-03-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 8 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain O
131–239(109 aa)
|
Not recorded | CD CADMIUM ION × 1 B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.7;33% PEG 2000, 0.2M CDCL2, 0.1M BIS- TRIS-PROPANE, PH 6.7, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 6.70
|
Resolution 2.60 Å R-free 0.244 |
| 3MNV Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment Deposited 2010-04-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
133–239(107 aa)
Fragment:FUSION PROTEIN between mouse Fv and a human Fc
|
Not recorded | SO4 SULFATE ION × 4 EDO 1,2-ETHANEDIOL × 3 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;298 K;Qiagen AmSO4 suite, reservoir: 2.2 M ammonium sulfate, 0.2 M lithium nitrate. Drop: 0.5 uL protein + 0.5 uL reservoir., VAPOR DIFFUSION, temperature 298K
|
Resolution 2.40 Å R-free 0.228 |
| 3MNV Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment Deposited 2010-04-22 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
133–239(107 aa)
Fragment:FUSION PROTEIN between mouse Fv and a human Fc
|
Not recorded | SO4 SULFATE ION × 2 EDO 1,2-ETHANEDIOL × 1 NO3 NITRATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;298 K;Qiagen AmSO4 suite, reservoir: 2.2 M ammonium sulfate, 0.2 M lithium nitrate. Drop: 0.5 uL protein + 0.5 uL reservoir., VAPOR DIFFUSION, temperature 298K
|
Resolution 2.40 Å R-free 0.228 |
| 3MNW Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived peptide in a helical conformation Deposited 2010-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain A
126–239(114 aa)
Fragment:mouse Fv,human Fc
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.2;298 K;Reservoir: Qiagen Classics II screen H10 (0.2 M K Na tartrate, 20% PEG 3350). Drop: 0.6 uL protein + 0.4 uL reservoir., pH 7.2, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.20 Å R-free 0.253 |
| 3MNW Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived peptide in a helical conformation Deposited 2010-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 6 PDB declaration: hexameric |
Chain A
126–239(114 aa)
Fragment:mouse Fv,human Fc
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.2;298 K;Reservoir: Qiagen Classics II screen H10 (0.2 M K Na tartrate, 20% PEG 3350). Drop: 0.6 uL protein + 0.4 uL reservoir., pH 7.2, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.20 Å R-free 0.253 |
| 3MNZ Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived peptide bearing Ala substitutions in a helical conformation Deposited 2010-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain A
126–239(114 aa)
Fragment:mouse Fv,human Fc
|
Not recorded | NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.2;298 K;Reservoir: Qiagen Classics II, condition with 0.2 M K Na tartrate, 20% PEG 3350. Drop: 0.6 uL protein + 0.4 uL reservoir, pH 7.2, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.80 Å R-free 0.215 |
| 3PGF Crystal structure of maltose bound MBP with a conformationally specific synthetic antigen binder (sAB) Deposited 2010-11-01 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 3 PDB declaration: trimeric |
Chain L
132–239(108 aa)
|
Not recorded | IMD IMIDAZOLE × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;292 K;19% PEG 3400, 8% Tacsimate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 2.10 Å R-free 0.227 |
| 4D9Q Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D Deposited 2012-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain L
130–238(109 aa)
|
Not recorded | GOL GLYCEROL × 3 ZN ZINC ION × 4 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;292 K;0.1 M MES pH 6.5, 25% PEG 550 MME, 0.01 M zinc sulfate and 3% 6-aminohexanoic acid, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
Resolution 2.28 Å R-free 0.230 |
| 4D9Q Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D Deposited 2012-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain D
130–238(109 aa)
|
Not recorded | GOL GLYCEROL × 7 ZN ZINC ION × 3 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;292 K;0.1 M MES pH 6.5, 25% PEG 550 MME, 0.01 M zinc sulfate and 3% 6-aminohexanoic acid, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
Resolution 2.28 Å R-free 0.230 |
| 4D9Q Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D Deposited 2012-01-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 6 PDB declaration: hexameric |
Chain D
130–238(109 aa)
Chain L
130–238(109 aa)
|
Not recorded | GOL GLYCEROL × 10 ZN ZINC ION × 7 SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;292 K;0.1 M MES pH 6.5, 25% PEG 550 MME, 0.01 M zinc sulfate and 3% 6-aminohexanoic acid, VAPOR DIFFUSION, SITTING DROP, temperature 292K
|
Resolution 2.28 Å R-free 0.230 |
| 4NUG Crystal structure of HIV-1 broadly neutralizing antibody PGT151 Deposited 2013-12-03 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
132–239(108 aa)
|
Not recorded | P6G HEXAETHYLENE GLYCOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 4.2;293.15 K;40% PEG 3350, 0.1M phosphate-citrate, pH 4.2, VAPOR DIFFUSION, temperature 293.15K
|
Resolution 1.86 Å R-free 0.207 |
| 4NWT Crystal structure of the anti-human NGF Fab APE1531 Deposited 2013-12-06 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
131–239(109 aa)
|
Not recorded | MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 ACT ACETATE ION × 4 PGE TRIETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;295 K;12% PEG 20000, 0.1M NaCl, 0.1M MES pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 295K
|
Resolution 1.75 Å R-free 0.181 |
| 4NWU Crystal structure of APE1551, an anti-human NGF Fab with a nine amino acid insertion in CDR H1 Deposited 2013-12-06 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;295 K;16% PEG 6000, 0.1 M Citric acid pH6.0-7.0, VAPOR DIFFUSION, SITTING DROP, temperature 295K
|
Resolution 1.60 Å R-free 0.198 |
| 5VIY BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 Deposited 2017-04-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 16 PDB declaration: hexadecameric |
Chain L
132–239(108 aa)
Chain N
132–239(108 aa)
Chain P
132–239(108 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 13 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 6.20 Å |
| 5VJ6 BG505 SOSIP.664 in complex with broadly neutralizing antibodies PG9 and 8ANC195 Deposited 2017-04-18 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 14 PDB declaration: tetradecameric |
Chain N
132–239(108 aa)
Chain P
132–239(108 aa)
Chain R
132–239(108 aa)
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 11.50 Å |
| 5VKK Crystal structure of Fab fragment of anti-CD22 Epratuzumab Deposited 2017-04-21 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
126–239(114 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;85 mM Tris, pH 8.5, 25.5%
PEG 4000 (w/v), 170 mM sodium acetate and 15% glycerol
|
Resolution 2.01 Å R-free 0.237 |
| 5VKK Crystal structure of Fab fragment of anti-CD22 Epratuzumab Deposited 2017-04-21 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
126–239(114 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;85 mM Tris, pH 8.5, 25.5%
PEG 4000 (w/v), 170 mM sodium acetate and 15% glycerol
|
Resolution 2.01 Å R-free 0.237 |
| 5VL3 CD22 d1-d3 in complex with therapeutic Fab Epratuzumab Deposited 2017-04-24 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 3 PDB declaration: trimeric |
Chain L
126–239(114 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;20 mM Tris pH 8.0 and 150 mM
NaCl, 5mg/mL
|
Resolution 3.10 Å R-free 0.295 |
| 5VL3 CD22 d1-d3 in complex with therapeutic Fab Epratuzumab Deposited 2017-04-24 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer;Protein × 3 PDB declaration: trimeric |
Chain B
126–239(114 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;20 mM Tris pH 8.0 and 150 mM
NaCl, 5mg/mL
|
Resolution 3.10 Å R-free 0.295 |
| 5VL3 CD22 d1-d3 in complex with therapeutic Fab Epratuzumab Deposited 2017-04-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer;Protein × 3 PDB declaration: trimeric |
Chain D
126–239(114 aa)
|
Not recorded | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;20 mM Tris pH 8.0 and 150 mM
NaCl, 5mg/mL
|
Resolution 3.10 Å R-free 0.295 |
| 5VL3 CD22 d1-d3 in complex with therapeutic Fab Epratuzumab Deposited 2017-04-24 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Other combination Heteromer;Protein × 3 PDB declaration: trimeric |
Chain F
126–239(114 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;20 mM Tris pH 8.0 and 150 mM
NaCl, 5mg/mL
|
Resolution 3.10 Å R-free 0.295 |
| 5VOD Crystal structure of HCMV Pentamer in complex with neutralizing antibody 9I6 Deposited 2017-05-02 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 7 PDB declaration: heptameric |
Chain L
123–239(117 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.2;293 K;10% (wt/vol) PEG methyl ether 500
0.1 M MES pH 6.2
0.00001 M phenol
|
Resolution 5.90 Å R-free 0.299 |
| 5VOD Crystal structure of HCMV Pentamer in complex with neutralizing antibody 9I6 Deposited 2017-05-02 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer;Protein × 14 PDB declaration: tetradecameric |
Chain L
123–239(117 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.2;293 K;10% (wt/vol) PEG methyl ether 500
0.1 M MES pH 6.2
0.00001 M phenol
|
Resolution 5.90 Å R-free 0.299 |
| 5VQM Clostridium difficile TcdB-GTD bound to PA41 Fab Deposited 2017-05-09 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain L
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;294 K;0.1 M Bis-Tris pH 5.5
1 M NaCl
11% PEG3350
|
Resolution 2.79 Å R-free 0.292 |
| 5VQM Clostridium difficile TcdB-GTD bound to PA41 Fab Deposited 2017-05-09 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 5.5;294 K;0.1 M Bis-Tris pH 5.5
1 M NaCl
11% PEG3350
|
Resolution 2.79 Å R-free 0.292 |
| 5W42 Crystal structure of human monoclonal antibody H3v-47 in complex with influenza virus hemagglutinin from A/Minnesota/11/2010 (H3N2) Deposited 2017-06-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 12 PDB declaration: dodecameric |
Chain L
131–239(109 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5;277 K;10% (v/v) 2-methyl-2,4-pentanediol (MPD), 0.1M MES (pH 5.0)
|
Resolution 3.57 Å R-free 0.228 |
| 5XRQ Crystal structure of human monoclonal antibody H3v-47 Deposited 2017-06-09 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;20% (w/v) polyethylene glycol (PEG) 6000, 0.1 M sodium citrate (pH 5.0)
|
Resolution 2.60 Å R-free 0.214 |
| 5XRQ Crystal structure of human monoclonal antibody H3v-47 Deposited 2017-06-09 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;20% (w/v) polyethylene glycol (PEG) 6000, 0.1 M sodium citrate (pH 5.0)
|
Resolution 2.60 Å R-free 0.214 |
| 6APD Crystal structure of RSV F bound by AM22 and the infant antibody ADI-19425 Deposited 2017-08-17 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 15 PDB declaration: pentadecameric |
Chain E
132–239(108 aa)
Chain G
132–239(108 aa)
Chain I
132–239(108 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;10% PEG 4000
10% 2-propanol
0.1 M sodium citrate pH 5.5
|
Resolution 4.10 Å R-free 0.256 |
| 6ARP Structure of a mutant Cetuximab Fab fragment Deposited 2017-08-23 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
132–239(108 aa)
|
Not recorded | SO4 SULFATE ION × 3 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium citrate, 1.6 M ammonium sulfate, 5% glycerol
|
Resolution 1.70 Å R-free 0.197 |
| 6ARP Structure of a mutant Cetuximab Fab fragment Deposited 2017-08-23 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
132–239(108 aa)
|
Not recorded | SO4 SULFATE ION × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium citrate, 1.6 M ammonium sulfate, 5% glycerol
|
Resolution 1.70 Å R-free 0.197 |
| 6ARU Structure of Cetuximab Fab mutant in complex with EGFR extracellular domain Deposited 2017-08-23 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 3 PDB declaration: trimeric |
Chain B
132–239(108 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;150 mM ammonium sulfate, 16.5% PEG3350, 10 mM cadmium chloride, 100 mM imidazole, 5% glycerol
|
Resolution 3.20 Å R-free 0.267 |
| 6BFT Structure of Bevacizumab Fab mutant in complex with VEGF Deposited 2017-10-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 6 PDB declaration: hexameric |
Chain B
130–239(110 aa)
Chain L
130–239(110 aa)
|
Not recorded | SO4 SULFATE ION × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;293 K;100 mM MES, 6.0, 225 mM ammonium sulfate, 13% PEG4000, 10% isopropanol
|
Resolution 2.55 Å R-free 0.220 |
| 6BKC Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neutralizing antibody AR3B Deposited 2017-11-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain L
131–239(109 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.7;293 K;20% (w/v) PEG 3500, 0.2M Li-chloride
|
Resolution 2.60 Å R-free 0.276 |
| 6DC4 RSV-neutralizing human antibody AM22 Deposited 2018-05-04 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain L
132–239(108 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 17 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.02 M 1,6-Hexanediol, 0.02 M 1-Butanol, 0.02 M 1,2-Propanediol (racemic), 0.02 M 2-Propanol, 0.02 M 1,4-Butanediol, 0.02 M 1,3-Propanediol, 0.1 M MES/imidazole pH 6.5, 10% PEG 8000, 20% ethylene glycol
|
Resolution 1.70 Å R-free 0.205 |
| 6DC5 RSV prefusion F in complex with AM22 Fab Deposited 2018-05-04 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 3 PDB declaration: trimeric |
Chain C
132–239(108 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
|
Resolution 3.50 Å R-free 0.280 |
| 6DC5 RSV prefusion F in complex with AM22 Fab Deposited 2018-05-04 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 3 PDB declaration: trimeric |
Chain F
132–239(108 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
|
Resolution 3.50 Å R-free 0.280 |
| 6DC5 RSV prefusion F in complex with AM22 Fab Deposited 2018-05-04 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Insufficient information Heteromer;Protein × 3 PDB declaration: trimeric |
Chain I
132–239(108 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
|
Resolution 3.50 Å R-free 0.280 |
| 6DCQ Ectodomain of full length, wild type HIV-1 glycoprotein clone PC64M18C043 in complex with PGT151 Fab Deposited 2018-05-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 10 PDB declaration: decameric |
Chain L
132–239(108 aa)
Chain N
132–239(108 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 21 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4;Detergent removed with Biobeads prior to grid freezing
cryo-EM vitrification conditions
Cryogen ETHANE;Blot force 0
Blot time 5 sec
|
Resolution 3.10 Å |
| 6E4X Human antibody S5V2-29 in complex with influenza hemagglutinin A/Texas/50/2012 (H3N2) Deposited 2018-07-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 3 PDB declaration: trimeric |
Chain Y
122–239(118 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;291.15 K;100 mM magnesium sulfate, 100 mM PIPES, pH 6.0, 30% PEG400
|
Resolution 2.25 Å R-free 0.225 |
| 6NZ7 Crystal structure of broadly neutralizing Influenza A antibody 429 B01 in complex with Hemagglutinin Hong Kong 1968 Deposited 2019-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain L
130–239(110 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;300 K;10 % PEG8000 (w/v), 100 mM Tris/Cl, pH 8.5 and 7.5 % 1,6-hexanediol (w/v)
|
Resolution 2.95 Å R-free 0.267 |
| 6NZ7 Crystal structure of broadly neutralizing Influenza A antibody 429 B01 in complex with Hemagglutinin Hong Kong 1968 Deposited 2019-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain I
130–239(110 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;300 K;10 % PEG8000 (w/v), 100 mM Tris/Cl, pH 8.5 and 7.5 % 1,6-hexanediol (w/v)
|
Resolution 2.95 Å R-free 0.267 |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6OKQ Crystal structure of the SF12 Fab Deposited 2019-04-14 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain E
131–239(109 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;100 mM HEPES, pH 7.5, 1.8 M sodium formate
|
Resolution 3.20 Å R-free 0.299 |
| 6UC5 Fab397 in complex with NPNA peptide Deposited 2019-09-13 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain L
122–238(117 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293.15 K;0.1 M HEPES, pH 6.62, 22% w/v PEG4000
|
Resolution 1.75 Å R-free 0.225 |
| 7CZQ S protein of SARS-CoV-2 in complex bound with P2B-1A10 Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 7 PDB declaration: heptameric |
Chain K
122–239(118 aa)
Chain N
122–239(118 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 7CZR S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 7 PDB declaration: heptameric |
Chain K
130–239(110 aa)
Chain N
130–239(110 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 30 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å |
| 7CZS S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 9 PDB declaration: nonameric |
Chain K
130–239(110 aa)
Chain M
130–239(110 aa)
Chain N
130–239(110 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 31 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å |
| 7CZU S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 7 PDB declaration: heptameric |
Chain K
122–239(118 aa)
Chain N
122–239(118 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 7CZV S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 9 PDB declaration: nonameric |
Chain K
122–239(118 aa)
Chain M
122–239(118 aa)
Chain N
122–239(118 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 31 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 7CZX S protein of SARS-CoV-2 in complex bound with P5A-1B9 Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 9 PDB declaration: nonameric |
Chain K
130–239(110 aa)
Chain M
130–239(110 aa)
Chain N
130–239(110 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 33 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 7D00 S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 7 PDB declaration: heptameric |
Chain K
130–239(110 aa)
Chain N
130–239(110 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å |
39 other PDB entries and 66 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | Q8TCD0_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 112–219; UniProt 132–239 |